Form 4: Century Therapeutics CFO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Morgan Conn, CFO of Century Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- Morgan Conn, the Chief Financial Officer of Century Therapeutics, Inc. (IPSC), filed a Form 4 on March 12, 2025, reporting transactions related to the company's securities.
- On March 11, 2025, Conn acquired 19,500 shares of common stock through restricted stock units (RSUs) and was granted an option to purchase 19,500 shares of common stock.
- The RSUs vest 25% on March 11, 2026, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
- The stock options vest 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
- The exercise price of the stock options is $0.601 per share, and they expire on March 11, 2035.
- Following these transactions, Conn directly owns 79,648 shares of Century Therapeutics common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of equity-based compensation aligns management's interests with shareholders, which is generally viewed favorably. There are no indications of negative news or concerns.
Positives
- The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedules of the RSUs and stock options incentivize continued service and commitment from the CFO.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules suggest a continued commitment from the CFO.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders.
Stakeholder Impact
- Shareholders may view the grant of RSUs and stock options to the CFO positively, as it aligns his interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of transaction: Grant of RSUs and stock options. |
| 03/11/2026 | First vesting date for 25% of RSUs and stock options. |
| 03/11/2035 | Expiration date of the stock options. |
| 03/12/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.